Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy

Figures & data

Figure 2. Nucleoside modification of mRNA for immune escape.

Figure 3. Different injection routes of gene delivery are outlined.

Figure 4. Systemic delivery of modified mRNA for gene therapy. A. Diagram of formulating modified mRNA into a liposome-protamine-RNA (LPR) complex. B. Proliferation capacity of the surviving H460 cells after HSV-tk/GCV therapy, determined by clonogenic assay. C. Tumor growth inhibition of H460 non-small cell lung cancer after HSV-tk/GCV therapy by systemic delivery of modified mRNA in the LPR.

Figure 5. Evaluating in vivo transfection efficiency of naked or nanoparticle-based modified (ARCA) mRNA according to the administration routes. A. Bioluminescence in C57BL/6 mice transfected intranasally with 4 μg of p/mLuc and n/mLuc over a 4-h time period. B. Bioluminescence in C57BL/6 mice transfected subcutaneously at the base of the ear pinna with p/mLuc and n/mLuc (in NaAc and RL) at 4 h. C. Bioluminescence signal in BALB/c mice intravenously administrated with 26 μg of p/mLuc and m/Luc at 8 h time points with respective color scales.

Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002;9:1647-52

 PubMed Web of Science ®Google Scholar

Wang Y, Su HH, Yang Y, et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther 2013;21:358-67

 PubMed Web of Science ®Google Scholar

Phua KK, Leong KW, Nair SK. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J Control Release 2013;166(3):227-33

 PubMed Web of Science ®Google Scholar